Surgery Partners reports Q2 adjusted EPS 17c, consensus 14c

Reports Q2 revenue $826.2M, consensus $816.96M. Eric Evans, Chief Executive Officer, stated, “We are proud to report strong growth in Adjusted EBITDA and revenue, demonstrating the strength of our operational strategy as we capitalize on the continued momentum in the ambulatory surgery industry. Our continued focus on maximizing portfolio performance, optimistic outlook on surgical trends and regulatory landscape, and focus on exceptional clinical quality and value, positions us for continued growth in 2025 and beyond. Our growth is the result of a relentless focus on excellence and differentiation in our core short-stay surgical service lines. In line with our commitment to enhance shareholder value, we are actively evaluating portfolio optimization opportunities to expedite leverage reduction, accelerate cash flow generation and provide increased flexibility to self-fund our growth algorithm following the conclusion of the recent strategic process.”